Candriam SCA’s Bicara Therapeutics BCAX Stock Holding History

Candriam SCA’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Buy	373,380 +134,558	+56%	+$3M	0.05%	276
2026 Q1	$4.75M	Buy	+238,822	New	+$4.11M	0.02%	402

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Candriam SCA's BCAX Position: Q2 2026 in Review

Candriam SCA increased its Bicara Therapeutics (BCAX) stake by 56% in Q2 2026, buying an estimated $3M and bringing the position to 373,380 shares worth $11.1M. The position accounts for 0.05% of the portfolio, ranked #276.

Candriam SCA first reported a position in BCAX in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

Candriam SCA held 373,380 shares of Bicara Therapeutics worth $11.1M as of Q2 2026.
Candriam SCA bought 134,558 Bicara Therapeutics shares in Q2 2026, an estimated $3M.
Bicara Therapeutics made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #276 holding.
Candriam SCA first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 2 quarters since.
172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.